Unusual Volume Biotech Stocks: Compugen Ltd (NASDAQ:CGEN), Sinovac Biotech (NASDAQ:SVA), Enzymotec (NASDAQ:ENZY), Cempra (NASDAQ:CEMP)

Over the past three years, using its in-silico discovery platform for predictive drug discovery (i.e. computer models and algorithms), Compugen Ltd. (USA) (NASDAQ:CGEN) has developed a hugely compelling drug Pipeline across several clinical areas. Compugen Ltd. (USA) (NASDAQ:CGEN) stock performance was -20.14% in last session and finished the day at $11.34. Traded volume was 22,668.00 shares in the last session and the average volume of the stock remained 500,829.00 shares. The beta of the stock remained 1.77. Compugen Ltd. (USA) (NASDAQ:CGEN) insider ownership is 10.04%.

Sinovac Biotech Ltd. (NASDAQ:SVA) rallied on Thursday after the development-stage drugmaker said its Enterovirus 71 vaccine was nearly perfect protecting infants and young children from herpangina and the coxsackie virus during Phase III. Sinovac Biotech Ltd. (NASDAQ:SVA) dropped -1.94% to $6.57 yesterday on volume of 0.00 shares. The intra-day range of the stock was $6.51 – $7.10. Sinovac Biotech Ltd. (NASDAQ:SVA) has a market capitalization of 363.86 million.

Enzymotec Ltd (NASDAQ:ENZY) announced the pricing of a registered secondary public offering.
Enzymotec Ltd (NASDAQ:ENZY)’s stock on Februry 28, 2014 reported a lower of -4.62% to the closing price of $27.90. Its fifty two weeks range is $14.25 – $35.12. The total market capitalization recorded 601.33 million. The overall volume in the last trading session was 0.00 shares. In its share capital, Enzymotec Ltd (NASDAQ:ENZY) has 21.55 million outstanding shares.

Cempra Inc. (NASDAQ:CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. On Friday, shares of Cempra Inc. (NASDAQ:CEMP) dropped -12.18% to close the day at $11.39. Company return on investment (ROI) is – and its monthly performance is recorded as -3.39%. Cempra Inc. (NASDAQ:CEMP) quarterly revenue growth is -8.00%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone